Galit Denkberg

Title: Galit Denkberg: Innovator in Antibody Research

Introduction

Galit Denkberg is a prominent inventor based in Nofit, Israel, known for his significant contributions to the field of antibody research. With a total of four patents to his name, Denkberg has made strides in developing affinity binding entities that have potential applications in diagnostics and therapy.

Latest Patents

Denkberg's latest patents include innovative compositions that feature affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity. These compositions are designed to bind to specific cells, such as HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP, or HLA-A2/TyrD+ cells, which can be utilized in both diagnostics and therapeutic settings. Another notable patent involves antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA-restricted manner, specifically targeting HLA-A2/TyrD369-377. This patent also includes complementary determining region (CDR) sequences of heavy and light chain antibodies, along with methods for using these antibodies in cancer treatment.

Career Highlights

Throughout his career, Galit Denkberg has worked with esteemed organizations, including the Technion Research & Development Foundation Limited. His work has focused on advancing the understanding and application of antibody technology, contributing to the development of novel therapeutic strategies.

Collaborations

Denkberg has collaborated with notable colleagues, including Yoram Reiter and Mira Peled Kamar, who have contributed to his research endeavors.

Conclusion

Galit Denkberg's innovative work in antibody research has led to significant advancements in the field, particularly in the development of targeted therapies for cancer. His contributions continue to shape the landscape of medical research and therapeutic applications.